SLS — Sellas Life Sciences Cashflow Statement
0.000.00%
Last trade - 00:00- $64.11m
- $45.69m
Annual cashflow statement for Sellas Life Sciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -19.3 | -16.8 | -20.7 | -41.3 | -37.3 |
| Deferred Taxes | |||||
| Non-Cash Items | 2.86 | 0.773 | 2.53 | 1.85 | 2.58 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -1.11 | 5.59 | -7.62 | 15.6 | 3.35 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -17.6 | -10.4 | -26 | -23.8 | -31.4 |
| Capital Expenditures | — | — | — | -4.5 | -5.5 |
| Purchase / Acquisition of Intangibles | |||||
| Cash from Investing Activities | — | — | — | -4.5 | -5.5 |
| Financing Cash Flow Items | — | — | — | 0.085 | -0.031 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 19.6 | 38.4 | 12.1 | 24.1 | 22.3 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 1.93 | 28 | -13.9 | -4.23 | -14.6 |